| Enhanced cancer immunotherapy by chimeric antigen receptor–modified T cells engineered to secrete checkpoint inhibitors SI Li, N Siriwon, X Zhang, S Yang, T Jin, F He, YJ Kim, J Mac, Z Lu, ... Clinical cancer research 23 (22), 6982-6992, 2017 | 283 | 2017 |
| Therapeutic strategies for targeting cancer stem cells YJ Kim, EL Siegler, N Siriwon, P Wang J Cancer Metastasis Treat 2, 233-42, 2016 | 118 | 2016 |
| CAR-T cells surface-engineered with drug-encapsulated nanoparticles can ameliorate intratumoral T-cell hypofunction N Siriwon, YJ Kim, E Siegler, X Chen, JA Rohrs, Y Liu, P Wang Cancer immunology research 6 (7), 812-824, 2018 | 117 | 2018 |
| Masked chimeric antigen receptor for tumor-specific activation X Han, PD Bryson, Y Zhao, GE Cinay, S Li, Y Guo, N Siriwon, P Wang Molecular Therapy 25 (1), 274-284, 2017 | 98 | 2017 |
| Combination cancer therapy using chimeric antigen receptor-engineered natural killer cells as drug carriers EL Siegler, YJ Kim, X Chen, N Siriwon, J Mac, JA Rohrs, PD Bryson, ... Molecular Therapy 25 (12), 2607-2619, 2017 | 82 | 2017 |
| Specific functions of the Wnt signaling system in gene regulatory networks throughout the early sea urchin embryo M Cui, N Siriwon, E Li, EH Davidson, IS Peter Proceedings of the National Academy of Sciences 111 (47), E5029-E5038, 2014 | 82 | 2014 |
| Development of a nanoparticle-based immunotherapy targeting PD-L1 and PLK1 for lung cancer treatment M Reda, W Ngamcherdtrakul, MA Nelson, N Siriwon, R Wang, HY Zaidan, ... Nature communications 13 (1), 4261, 2022 | 80 | 2022 |
| Enhancing gene delivery of adeno-associated viruses by cell-permeable peptides Y Liu, YJ Kim, M Ji, J Fang, N Siriwon, LI Zhang, P Wang Molecular Therapy-Methods & Clinical Development 1, 2014 | 78 | 2014 |
| PLK1 and EGFR targeted nanoparticle as a radiation sensitizer for non-small cell lung cancer M Reda, W Ngamcherdtrakul, S Gu, DS Bejan, N Siriwon, JW Gray, ... Cancer letters 467, 9-18, 2019 | 57 | 2019 |
| Combination drug delivery via multilamellar vesicles enables targeting of tumor cells and tumor vasculature Y Liu, YJ Kim, N Siriwon, JA Rohrs, Z Yu, P Wanga Biotechnology and Bioengineering 115 (6), 1403-1415, 2018 | 33 | 2018 |
| Targeted Nanoparticle for Co-delivery of HER2 siRNA and a Taxane to Mirror the Standard Treatment of HER2+ Breast Cancer: Efficacy in Breast Tumor and Brain Metastasis YW Ngamcherdtrakul W, Bejan DS, Cruz-Muñoz W, Reda M, Zaidan HY, Siriwon N ... Small, e2107550, 2022 | 28 | 2022 |
| Generation of targeted adeno-associated virus (AAV) vectors for human gene therapy Y Liu, N Siriwon, J A Rohrs, P Wang Current Pharmaceutical Design 21 (22), 3248-3256, 2015 | 25 | 2015 |
| Selective capture of radionuclides (U, Pu, Th, Am and Co) using functional nanoporous sorbents W Yantasee, GE Fryxell, K Pattamakomsan, T Sangvanich, RJ Wiacek, ... Journal of hazardous materials 366, 677-683, 2019 | 21 | 2019 |
| Targeted Nanoparticle for Co‐delivery of HER2 siRNA and a Taxane to Mirror the Standard Treatment of HER2+ Breast Cancer: Efficacy in Breast Tumor and Brain … W Ngamcherdtrakul, DS Bejan, W Cruz‐Muñoz, M Reda, HY Zaidan, ... Small 18 (11), 2270050, 2022 | 3 | 2022 |
| Evaluation of hematological and biochemical activity of Bauhinia strychnifolia Craib leaves ethanol extracts in normal albino rats J Kwansang, W Damjuti, N Siriwon Afr J Pharm Pharmacol 15, 48-52, 2021 | 3 | 2021 |
| COMPOSITIONS AND METHODS OF TREATMENT OF CANCER P Wang, N SIRIWON, S Li | 1 | 2020 |
| Development of novel immunotherapy based on nanoparticle co-delivering PLK1 and PD-L1 inhibitors for lung cancer treatment M Reda, W Ngamcherdtrakul, M Nelson, N Siriwon, R Wang, H Zaidan, ... | | 2022 |
| Compositions and methods for treating cancer P Wang, N Siriwon, S Li US Patent App. 16/603,792, 2021 | | 2021 |
| Adoptive transfer of car t cells with surface-conjugated drug-loaded nanoparticles and uses thereof P Wang, YJ Kim, N Siriwon US Patent App. 16/485,033, 2019 | | 2019 |
| Compositions and methods for treating cancer P Wang, N SIRIWON, S Li | | 2018 |
